LOGIN  |  REGISTER
Chimerix
Amneal Pharmaceuticals

Apollo Medical Holdings Schedules 2023 First Quarter Financial Results Release and Conference Call

April 26, 2023 | Last Trade: US$32.19 0.66 2.09

ALHAMBRA, Calif., April 26, 2023 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced that it will release financial results for the first quarter ended March 31, 2023, after the close of the stock market on Monday, May 8, 2023. The Company will discuss those results in a conference call at 2:30 p.m. PT/5:30 p.m. ET that same day.

Participant Dial-in Numbers

 

U.S. & Canada (Toll-Free):

(877) 858-9810

International (Toll):

(201) 689-8517

To access the call, please dial in approximately five minutes before start time. An accompanying slide presentation will be available in PDF format on the "IR Calendar" page of the Company's website (https://www.apollomed.net/investors/news-events/ir-calendar) after issuance of the earnings release.

Webcast

The call will also be available via online webcast at: https://event.choruscall.com/mediaframe/webcast.html?webcastid=AlyzvuQn.

Those who are unable to attend the live conference call may access the recording at the above webcast link, which will be made available shortly after the conclusion of the call.

About Apollo Medical Holdings, Inc.

ApolloMed is a leading physician-centric, technology-powered, risk-bearing healthcare management company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high quality care to patients in a cost-effective manner.

Headquartered in Alhambra, California, ApolloMed's subsidiaries and affiliates include management services organizations (MSOs), affiliated independent practice associations (IPAs), and entities participating in the Centers for Medicare & Medicaid Services Innovation Center (CMMI) innovation models. For more information, please visit www.apollomed.net.

FOR MORE INFORMATION, PLEASE CONTACT:

Investor Relations
(626) 943-6491
This email address is being protected from spambots. You need JavaScript enabled to view it.

Carolyne Sohn, The Equity Group
(408) 538-4577
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB